Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 478

The DOI matches its Crossref record.

Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure

Open access
Slawsky, Mara T., Colucci, Wilson S., Gottlieb, Stephen S., Greenberg, Barry H., Haeusslein, Ernest, Hare, Joshua, Hutchins, Steven, Leier, Carl V., LeJemtel, Thierry H., Loh, Evan, Nicklas, John, Ogilby, David, Singh, Bramah N., Smith, William·2000·Circulation

Abstract

Background—We determined the short-term hemodynamic and clinical effects of levosimendan, a novel calcium-sensitizing agent, in patients with decompensated heart failure. Methods and Results—One hundred forty-six patients with New York Heart Association functional class III or IV heart failure (mean left ventricular ejection fraction 21±1%) who had a pulmonary capillary wedge pressure ≥15 mm Hg and a cardiac index ≤2.5 L · min−1· m−2 were enrolled in a multicenter, double-blind, placebo-controlled study and randomized 2:1 to intravenous infusion of levosimendan or placebo. Drug infusions were uptitrated over 4 hours from an initial infusion rate of 0.1 μg · kg−1· min−1 to a maximum rate of 0.4 μg · kg−1· min−1 and maintained at the maximal tolerated infusion rate for an additional 2 hours. Levosimendan caused dose-dependent increases in stroke volume and cardiac index beginning with the lowest infusion rate and achieving maximal increases in stroke volume and cardiac index of 28% and 39%, respectively. Heart rate increased modestly (8%) at the maximal infusion rate and was not increased at the 2 lowest infusion rates. Levosimendan caused dose-dependent decreases in pulmonary capillary wedge, right atrial, pulmonary arterial, and mean arterial pressures. Levosimendan appeared to improve dyspnea and fatigue, as assessed by the patient and physician, and was not associated with a significant increase in adverse events. Conclusions—Levosimendan caused rapid dose-dependent improvement in hemodynamic function in patients with decompensated heart failure. These hemodynamic effects appeared to be accompanied by symptom improvement and were not associated with a significant increase in the number of adverse events. Levosimendan may be of value in the short-term management of patients with decompensated heart failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.102.18.2222

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 478

Metadata

Authors
Slawsky, M. T., Colucci, W. S., Gottlieb, S. S., Greenberg, B. H., Haeusslein, E., Hare, J., Hutchins, S., Leier, C. V., LeJemtel, T. H., Loh, E., Nicklas, J., Ogilby, D., Singh, B. N., & Smith, W.
Venue
Circulation
Published
2000-10-31
Volume
102
Issue
18
Pages
2222-2227
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2127139759
Cited by
478
References
0
FWCI
15.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure. https://app.cochat.ai/papers/10.1161/01.cir.102.18.2222
The paper
Slawsky, M. T., Colucci, W. S., Gottlieb, S. S., Greenberg, B. H., Haeusslein, E., Hare, J., Hutchins, S., Leier, C. V., LeJemtel, T. H., Loh, E., Nicklas, J., Ogilby, D., Singh, B. N., & Smith, W. (2000). Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure. Circulation. https://doi.org/10.1161/01.cir.102.18.2222

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.